229 related articles for article (PubMed ID: 29370305)
1. Alterations of HIV-1 envelope phenotype and antibody-mediated neutralization by signal peptide mutations.
Upadhyay C; Feyznezhad R; Yang W; Zhang H; Zolla-Pazner S; Hioe CE
PLoS Pathog; 2018 Jan; 14(1):e1006812. PubMed ID: 29370305
[TBL] [Abstract][Full Text] [Related]
2. Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes.
Upadhyay C; Feyznezhad R; Cao L; Chan KW; Liu K; Yang W; Zhang H; Yolitz J; Arthos J; Nadas A; Kong XP; Zolla-Pazner S; Hioe CE
PLoS Pathog; 2020 Dec; 16(12):e1009185. PubMed ID: 33370382
[TBL] [Abstract][Full Text] [Related]
3. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
4. A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization.
Wang W; Nie J; Prochnow C; Truong C; Jia Z; Wang S; Chen XS; Wang Y
Retrovirology; 2013 Feb; 10():14. PubMed ID: 23384254
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human immunodeficiency virus (HIV-1) infectivity by expression of poorly or broadly neutralizing antibodies against Env in virus-producing cells.
Wang Q; Zhang S; Nguyen HT; Sodroski J
J Virol; 2024 Feb; 98(2):e0159423. PubMed ID: 38289101
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage.
Reh L; Magnus C; Kadelka C; Kühnert D; Uhr T; Weber J; Morris L; Moore PL; Trkola A
PLoS Pathog; 2018 Jan; 14(1):e1006825. PubMed ID: 29370298
[TBL] [Abstract][Full Text] [Related]
7. Evolution of the Envelope Glycoprotein of HIV-1 Clade B toward Higher Infectious Properties over the Course of the Epidemic.
Bouvin-Pley M; Beretta M; Moreau A; Roch E; Essat A; Goujard C; Chaix ML; Moiré N; Martin L; Meyer L; Barin F; Braibant M
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567994
[TBL] [Abstract][Full Text] [Related]
8. Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States.
Johnson J; Zhai Y; Salimi H; Espy N; Eichelberger N; DeLeon O; O'Malley Y; Courter J; Smith AB; Madani N; Sodroski J; Haim H
J Virol; 2017 Aug; 91(15):. PubMed ID: 28490588
[TBL] [Abstract][Full Text] [Related]
9. Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.
Gift SK; Leaman DP; Zhang L; Kim AS; Zwick MB
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978711
[TBL] [Abstract][Full Text] [Related]
10. A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins.
Yuan T; Li J; Zhang MY
MAbs; 2011; 3(4):402-7. PubMed ID: 21540646
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 envelope glycan moieties modulate HIV-1 transmission.
Shen R; Raska M; Bimczok D; Novak J; Smith PD
J Virol; 2014 Dec; 88(24):14258-67. PubMed ID: 25275130
[TBL] [Abstract][Full Text] [Related]
12. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
McGuire AT; Glenn JA; Lippy A; Stamatatos L
J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
[TBL] [Abstract][Full Text] [Related]
13. Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth.
Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Hunter E; Derdeyn CA
PLoS Pathog; 2016 Nov; 12(11):e1005989. PubMed ID: 27851829
[TBL] [Abstract][Full Text] [Related]
14. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
[TBL] [Abstract][Full Text] [Related]
15. Introduction of exogenous epitopes in the variable regions of the human immunodeficiency virus type 1 envelope glycoprotein: effect on viral infectivity and the neutralization phenotype.
Wallace A; Stamatatos L
J Virol; 2009 Aug; 83(16):7883-93. PubMed ID: 19494007
[TBL] [Abstract][Full Text] [Related]
16. Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans.
Wu NR; Nicely NI; Lee EM; Reed RK; Watts BE; Cai F; Walkowicz WE; Aussedat B; Jones JA; Eaton A; Trama AM; Alam SM; Montefiori DC; Haynes BF; Saunders KO
PLoS Pathog; 2019 Dec; 15(12):e1008165. PubMed ID: 31841553
[TBL] [Abstract][Full Text] [Related]
17. Antibody responses to the HIV-1 envelope high mannose patch.
Daniels CN; Saunders KO
Adv Immunol; 2019; 143():11-73. PubMed ID: 31607367
[TBL] [Abstract][Full Text] [Related]
18. A Highly Unusual V1 Region of Env in an Elite Controller of HIV Infection.
Silver ZA; Dickinson GM; Seaman MS; Desrosiers RC
J Virol; 2019 May; 93(10):. PubMed ID: 30842322
[TBL] [Abstract][Full Text] [Related]
19. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.
Quiñones-Kochs MI; Buonocore L; Rose JK
J Virol; 2002 May; 76(9):4199-211. PubMed ID: 11932385
[TBL] [Abstract][Full Text] [Related]
20. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
